{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:16:19Z","timestamp":1791666979966,"version":"4.3.4"},"reference-count":85,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Ulcerative colitis (UC) is a chronic progressive inflammatory bowel disease, with evolutive potential for extension to the entire colon, development of complications and need for colectomy. Therapeutic goals in UC have moved from symptom control to more stringent outcomes such as endoscopic and histologic remission, which have been observed to correlate with improved long-term outcomes. Disease clearance, a composite endpoint simultaneously including clinical remission, endoscopic and histologic healing, has been recently proposed as the ultimate target. A treat-to-target approach, as endorsed by the STRIDE II consensus, with a tight monitoring and treatment escalation when predefined endpoints are not reached, is proposed as a strategy to achieve complete disease control. However, unlike Crohn\u2019s disease (CD), the evidence supporting this approach for the management of UC is limited and its implementation in routine clinical practice is not widely diffused. Recent real-life data show that almost half of UC patients are not adequately controlled with current therapies according to STRIDE II criteria, due to steroid overuse, persistent signs of inflammation, active extra-intestinal manifestations and impaired quality of life. This perspective paper explores current evidence and future directions on treat-to-target strategies in UC for clinical research and practice.<\/jats:p>","DOI":"10.3390\/jcm15020759","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:36:33Z","timestamp":1768898193000},"page":"759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treat-to-Target in Ulcerative Colitis: How Soon Is Now?"],"prefix":"10.3390","volume":"15","author":[{"given":"Laura","family":"Parisio","sequence":"first","affiliation":[{"name":"UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8766-5108","authenticated-orcid":false,"given":"Giuseppe","family":"Cuccia","sequence":"additional","affiliation":[{"name":"UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Privitera","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Castaldo","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-3310","authenticated-orcid":false,"given":"Luigi","family":"Carbone","sequence":"additional","affiliation":[{"name":"UOC Pronto Soccorso, Medicina d\u2019Urgenza e Medicina Interna, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-8981","authenticated-orcid":false,"given":"Laura Maria","family":"Minordi","sequence":"additional","affiliation":[{"name":"UOC di Radioterapia Oncologica ed Ematologia, Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-5402","authenticated-orcid":false,"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[{"name":"UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"IBD Unit-CEMAD (Centro Malattie Apparato Digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Horio, R., Kato, J., Ohta, Y., Taida, T., Saito, K., Iwasaki, M., Ozeki, Y., Koshibu, Y., Shu, N., and Furuya, M. (2024). Risk Factors for Clinical Relapse in Patients with Ulcerative Colitis Who Are in Clinical Remission but with Endoscopic Activity. JGH Open, 8.","DOI":"10.1002\/jgh3.70011"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/ajg.2016.418","article-title":"Histological Disease Activity as a Predictor of Clinical Relapse Among Patients with Ulcerative Colitis: Systematic Review and Meta-Analysis","volume":"111","author":"Park","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a Treatment Strategy of Tight Control for Rheumatoid Arthritis (the TICORA Study): A Single-Blind Randomised Controlled Trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of Joint Damage in Patients with Early Rheumatoid Arthritis Treated with High-dose Methotrexate with or without Concomitant Infliximab: Results from the ASPIRE Trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sharip, M.T., Brezina, B., De La Revilla Negro, J., Subramanian, S., Parkes, M., Raine, T., and Noor, N.M. (2025). A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International Survey. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030667"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1080\/03007995.2024.2410928","article-title":"Assessing Disease Control in Inflammatory Bowel Disease: A Real World Cross-Sectional Study in the UK (PODCAST-IBD)","volume":"40","author":"Steed","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.dld.2025.05.006","article-title":"IBD Impact on Quality of Life and Perception of Disease Activity in Italian Patients and Physicians: An IBD-PODCAST Study Sub Analysis","volume":"57","author":"Savarino","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10620-023-08220-9","article-title":"IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management","volume":"69","author":"Vega","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in Ulcerative Colitis","volume":"2","author":"Truelove","year":"1955","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Seow, C.H., Steinhart, A.H., and Griffiths, A.M. (2008). Traditional Corticosteroids for Induction of Remission in Crohn\u2019s Disease. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD006792.pub2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1542-3565(05)00759-7","article-title":"Effect of Systemic Corticosteroid Therapy on Risk for Intra-Abdominal or Pelvic Abscess in Non-Operated Crohn\u2019s Disease","volume":"3","author":"Agrawal","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: Results of Drug Treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gut.19.7.606","article-title":"Low Dose Steroids and Clinical Relapse in Crohn\u2019s Disease: A Controlled Trial","volume":"19","author":"Smith","year":"1978","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal Healing Is Associated with Improved Long-Term Outcomes of Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review Article: Defining Remission in Ulcerative Colitis: Review: Remission in Ulcerative Colitis","volume":"34","author":"Travis","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/17474124.2014.902302","article-title":"Mucosal Healing as a Treatment for IBD?","volume":"8","author":"Papi","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Viscido, A., Valvano, M., Stefanelli, G., Capannolo, A., Castellini, C., Onori, E., Ciccone, A., Vernia, F., and Latella, G. (2022). Systematic Review and Meta-Analysis: The Advantage of Endoscopic Mayo Score 0 over 1 in Patients with Ulcerative Colitis. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02157-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond Endoscopic Mucosal Healing in UC: Histological Remission Better Predicts Corticosteroid Use and Hospitalisation over 6 Years of Follow-Up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.gie.2017.07.028","article-title":"Impact of Mucosal Inflammation on Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"86","author":"Flores","year":"2017","journal-title":"Gastrointest. Endosc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as Induction and Maintenance Therapy for Moderately to Severely Active Ulcerative Colitis: Results from Three Phase 3, Multicentre, Double-Blind, Randomised Trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between Patient-Reported Outcomes, and Endoscopic and Histological Appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations","volume":"18","author":"Schreiber","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jairath, V., Zou, G., Wang, Z., Adsul, S., Colombel, J.-F., D\u2019Haens, G.R., Freire, M., Moran, G.W., Peyrin-Biroulet, L., and Sandborn, W.J. (2024). Determining the Optimal Treatment Target in Patients with Ulcerative Colitis: Rationale, Design, Protocol and Interim Analysis for the Randomised Controlled VERDICT Trial. BMJ Open Gastroenterol., 11.","DOI":"10.1136\/bmjgast-2023-001218"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating Patient Experience into Drug Development for Ulcerative Colitis: Development of the Urgency Numeric Rating Scale, a Patient-Reported Outcome Measure to Assess Bowel Urgency in Adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A New Measure of Health Status for Clinical Trials in Inflammatory Bowel Disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/j.1572-0241.2001.04682.x","article-title":"The Short Inflammatory Bowel Disease Questionnaire Is Reliable and Responsive to Clinically Important Change in Ulcerative Colitis","volume":"96","author":"Jowett","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in Patients with Inflammatory Bowel Disease","volume":"34","author":"Tinsley","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/03007995.2022.2081453","article-title":"Endoscopic Mucosal Healing and Histologic Remission in Ulcerative Colitis: A Systematic Literature Review of Clinical, Quality-of-Life and Economic Outcomes","volume":"38","author":"Pandey","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early Combined Immunosuppression for the Management of Crohn\u2019s Disease (REACT): A Cluster Randomised Controlled Trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of Tight Control Management on Crohn\u2019s Disease (CALM): A Multicentre, Randomised, Controlled Phase 3 Trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep Remission at 1 Year Prevents Progression of Early Crohn\u2019s Disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_38","first-page":"89","article-title":"A Cluster-Randomised Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn\u2019s Disease: React-2","volume":"10","author":"Jairath","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to Target versus Standard of Care for Patients with Crohn\u2019s Disease Treated with Ustekinumab (STARDUST): An Open-Label, Multicentre, Randomised Phase 3b Trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cgh.2022.05.055","article-title":"Early Ultrasound Response and Progressive Transmural Remission After Treatment with Ustekinumab in Crohn\u2019s Disease","volume":"21","author":"Kucharzik","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cgh.2014.03.035","article-title":"Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients with Quiescent Ulcerative Colitis","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/2050640614560785","article-title":"Pharmacological Intervention Based on Fecal Calprotectin Levels in Patients with Ulcerative Colitis at High Risk of a Relapse: A Prospective, Randomized, Controlled Study","volume":"3","author":"Lasson","year":"2015","journal-title":"UEG J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"i180","DOI":"10.1093\/ecco-jcc\/jjae190.0089","article-title":"DOP050 Target Achievement after 48 Weeks of Vedolizumab Treatment in Patients with Moderate to Severe Ulcerative Colitis: An Interim Analysis from the VERDICT Trial","volume":"19","author":"Jairath","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1053\/j.gastro.2022.10.005","article-title":"The Use of Intestinal Ultrasound in Ulcerative Colitis\u2014More Than a Mucosal Disease?","volume":"163","author":"Palmela","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/gutjnl-2019-319451","article-title":"Intestinal Ultrasound for Monitoring Therapeutic Response in Patients with Ulcerative Colitis: Results from the TRUST&UC Study","volume":"69","author":"Maaser","year":"2020","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ibd\/izad043","article-title":"Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study","volume":"30","author":"Goodsall","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/ibd\/izad274","article-title":"Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis","volume":"30","author":"Bots","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.cgh.2024.04.039","article-title":"AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary","volume":"22","author":"Chavannes","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ecco-jcc\/jjad071","article-title":"Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis","volume":"17","author":"Allocca","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Dolinger, M.T., Aronskyy, I., Spencer, E.A., Pittman, N., and Dubinsky, M.C. (2025). Early Intestinal Ultrasound Response to Biologic and Small Molecule Therapy Is Accurate to Predict Treat-to-Target Endoscopic Outcomes in Children with Ulcerative Colitis: Results from the Prospective Super Sonic-UC Study. J. Crohn\u2019s Colitis, 19.","DOI":"10.1093\/ecco-jcc\/jjaf075"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sagami, S., Odajima, K., Asonoma, K., Miyatani, Y., Nakano, M., Maeda, I., Hibi, T., and Kobayashi, T. (2025). Early Reduction in Rectal Wall Thickness on Transperineal Ultrasound Predicts Mucosal Healing in Ulcerative Colitis. J. Crohn\u2019s Colitis, 19.","DOI":"10.1093\/ecco-jcc\/jjaf141"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Goertz, R.S., Lueke, C., Schellhaas, B., Pfeifer, L., Wildner, D., Neurath, M.F., and Strobel, D. (2019). Acoustic Radiation Force Impulse (ARFI) Shear Wave Elastography of the Bowel Wall in Healthy Volunteers and in Ulcerative Colitis. Acta Radiol. Open, 8.","DOI":"10.1177\/2058460119840969"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Madsen, G.R., Wilkens, R., Attauabi, M., Ilvemark, J.F.K.F., Theede, K., Bjerrum, J.T., Bendtsen, F., Seidelin, J.B., Boysen, T., and Burisch, J. (2025). Intestinal Ultrasound as a Prognostic Tool in New-Onset Ulcerative Colitis\u2014A Copenhagen IBD Cohort Study. J. Crohn\u2019s Colitis, 19.","DOI":"10.1093\/ecco-jcc\/jjaf033"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cr\u0103ciun, R., Bumbu, A.L., Ichim, V.A., Tan\u021b\u0103u, A.I., and Tefas, C. (2025). Artificial Intelligence in Endoscopic and Ultrasound Imaging for Inflammatory Bowel Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124291"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40273-017-0601-6","article-title":"A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis","volume":"36","author":"Stawowczyk","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2020.05.010","article-title":"Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis","volume":"19","author":"Dulai","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/ecco-jcc\/jjw076","article-title":"Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis","volume":"10","author":"Ippolito","year":"2016","journal-title":"ECCOJC"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/apt.14526","article-title":"Fibrosis in Ulcerative Colitis Is Directly Linked to Severity and Chronicity of Mucosal Inflammation","volume":"47","author":"Gordon","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ecco-jcc\/jjv133","article-title":"Development of Fibrosis in Acute and Longstanding Ulcerative Colitis","volume":"9","author":"Meijer","year":"2015","journal-title":"ECCOJC"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/apt.14575","article-title":"Editorial: Ulcerative Colitis Submucosal Fibrosis and Inflammation: More than Just Strictures","volume":"47","author":"Magro","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gundersen, M.D., Goll, R., Fenton, C.G., Anderssen, E., S\u00f8rbye, S.W., Florholmen, J.R., and Paulssen, R.H. (2019). Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin. Transl. Gastroenterol., 10.","DOI":"10.14309\/ctg.0000000000000082"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shih, D.Q., Barrett, R., Zhang, X., Yeager, N., Koon, H.W., Phaosawasdi, P., Song, Y., Ko, B., Wong, M.H., and Michelsen, K.S. (2011). Constitutive TL1A (TNFSF15) Expression on Lymphoid or Myeloid Cells Leads to Mild Intestinal Inflammation and Fibrosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016090"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mi.2014.37","article-title":"Inhibition of a Novel Fibrogenic Factor Tl1a Reverses Established Colonic Fibrosis","volume":"7","author":"Shih","year":"2014","journal-title":"Mucosal Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000528312","article-title":"Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease","volume":"7","author":"Andoh","year":"2022","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wenxiu, J., Mingyue, Y., Fei, H., Yuxin, L., Mengyao, W., Chenyang, L., Jia, S., Hong, Z., Shih, D.Q., and Targan, S.R. (2021). Effect and Mechanism of TL1A Expression on Epithelial-Mesenchymal Transition during Chronic Colitis-Related Intestinal Fibrosis. Mediat. Inflamm., 2021.","DOI":"10.1155\/2021\/5927064"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis","volume":"28","author":"Ye","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A Antibody, Afimkibart, in Moderately-to-Severely Active Ulcerative Colitis (TUSCANY-2): A Multicentre, Double-Blind, Treat-through, Multi-Dose, Randomised, Placebo-Controlled, Phase 2b Trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"i162","DOI":"10.1093\/ecco-jcc\/jjac190.0127","article-title":"DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn\u2019s Disease: Phase 2a APOLLO-CD Study Results","volume":"17","author":"Feagan","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tavares De Sousa, H., and Magro, F. (2023). How to Evaluate Fibrosis in IBD?. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132188"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ibd\/izz197","article-title":"Making Qualitative Intestinal Stricture Quantitative: Embracing Radiomics in IBD","volume":"26","author":"Lin","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.bbrc.2009.03.104","article-title":"Up-Regulation of the Expression of Leucine-Rich A2-Glycoprotein in Hepatocytes by the Mediators of Acute-Phase Response","volume":"382","author":"Shirai","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1038\/s41598-025-89615-8","article-title":"Changes of Leucine-Rich Alpha 2 Glycoprotein Could Be a Marker of Changes of Endoscopic and Histologic Activity of Ulcerative Colitis","volume":"15","author":"Aoyama","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ishida, N., Sugiura, K., Miyazu, T., Tamura, S., Suzuki, S., Tani, S., Yamade, M., Iwaizumi, M., Hamaya, Y., and Osawa, S. (2020). Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients with Ulcerative Colitis in Clinical Remission. Clin. Transl. Gastroenterol., 11.","DOI":"10.14309\/ctg.0000000000000289"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","article-title":"Diagnostic Value of Anti-Integrin Av\u03b26 Antibodies in Ulcerative Colitis","volume":"56","author":"Marafini","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-Integrin Av\u03b26 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wils, P., Caron, B., D\u2019Amico, F., Danese, S., and Peyrin-Biroulet, L. (2022). Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154269"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2016.12.023","article-title":"Series: Pragmatic Trials and Real World Evidence: Paper 1. Introduction","volume":"88","author":"Zuidgeest","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1932296819832653","article-title":"The Expanding Role of Real-World Evidence Trials in Health Care Decision Making","volume":"14","author":"Klonoff","year":"2020","journal-title":"J. Diabetes. Sci. Technol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jclinepi.2016.12.022","article-title":"Series: Pragmatic Trials and Real World Evidence: Paper 6. Outcome Measures in the Real World","volume":"90","author":"Welsing","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Danese, S., Fiorino, G., Vicaut, E., Paridaens, K., Ugur, A., Clark, B., Vanasek, T., Stepek, D., D\u2019Amico, F., and West, R. (2024). Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis\u2014The OPTIMISE Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175147"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40271-015-0126-z","article-title":"Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients\u2019 Perspectives on Shared Decision Making","volume":"9","author":"Siegel","year":"2016","journal-title":"Patient"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000253862","article-title":"Patients\u2019 Preferences Regarding Shared Decision-Making in the Treatment of Inflammatory Bowel Disease: Results from a Patient-Empowerment Study","volume":"81","author":"Baars","year":"2010","journal-title":"Digestion"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.34172\/mejdd.2022.256","article-title":"Development of a Patient Decision Aid to Help People Living with Inflammatory Bowel Disease","volume":"14","author":"Tamizifar","year":"2022","journal-title":"Middle East J. Dig. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/759\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:56:07Z","timestamp":1768899367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":85,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020759"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020759","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}